Science & technology

Repairing the heart at the cellular level

More than two decades of regenerative-medicine science — from molecular biologics to whole-organ bioengineering — anchored by the foundational patents of Dr. Doris Taylor.

Lami-Pro™ · mechanism of action

Designed to reverse HFpEF — not manage it

Lami-Pro™ is a patent-pending biologic, delivered by transendocardial injection into targeted regions of the heart in HFpEF (heart failure with preserved ejection fraction). It attacks the disease through complementary mechanisms.

Cardiomyocyte modulation

Lowers cardiomyocyte stiffness, increases cardiomyocyte compliance, improving diastolic relaxation.

Anti-inflammatory

Shifts macrophages from pro-inflammatory M1 to reparative M2 phenotype.

Anti-fibrotic

Deactivates myofibroblasts and reduces collagen deposition and MMP activity.

Culmination

  • ↓ Cardiac stiffness
  • ↓ Fibrosis
  • ↓ Inflammation
  • ↑ Myocyte relaxation
  • ↑ Repair

Mechanistic activity demonstrated in preclinical human-tissue studies: human iPSC cardiomyocytes, ex vivo studies, and human failing heart-muscle samples. Provisional patent filed and converted in the U.S. and Europe.

Request additional scientific information →
Ventri-Pro™ · mechanism of action

A bioengineered patch designed to slow heart-failure progression

Ventri-Pro™ is a bioengineered cardiac-derived patch for heart failure with reduced ejection fraction (HFrEF), built on the same extracellular-matrix science as the rest of the platform. Applied to the failing ventricle in dilated heart failure, it is designed to mechanically stabilize the chamber and slow the remodeling that drives progressive dilation.

The bioactive scaffold is designed to promote vascularization and support a pro-reparative micro-environment — recruiting host cells and supporting regeneration before damage becomes irreversible. With demonstrated activity in preclinical models, it is being developed as a scalable, near-term candidate for the more than 500,000 patients who develop dilated heart failure each year.

Request additional scientific information →
Your-Heart process: decellularization to recellularization to patient-specific heart
The platform · Your-Heart™

From a "ghost heart" to a personalized organ

The cornerstone of Organamet's platform is perfusion decellularization — a technique Dr. Taylor pioneered that gently washes the cells out of a mammalian heart to leave a pristine extracellular-matrix scaffold, or "ghost heart."

That universal scaffold is then re-seeded with cells derived from a patient's own blood — induced pluripotent stem cells that can become any cell type in the body that is needed. The result is a bioengineered, patient-specific heart that the recipient's immune system recognizes as its own: no rejection, no lifelong immunosuppression, and no waiting for a donor.

The same decellularization and ECM-bioengineering science underpins Ventri-Pro™ and informs the bioactive matrix chemistry behind Lami-Pro™ — one platform, three products.

Request additional scientific information →
Intellectual property

A defensible, multi-layered IP estate

Products

Composition-of-matter and formulation patents covering the bioactive protein and bioengineered constructs

Manufacturing

Proprietary, scalable decellularization and biofabrication processes — developed with our strategic partners: ARMI | BioFabUSA, Advanced Solutions Life Sciences, and DEKA Research.

Delivery

Transendocardial delivery or robotic-assisted systems for precise image-guided administration

All Organamet Bio product candidates are investigational, have not been approved by FDA or any regulatory authority, and their safety and effectiveness have not been established. Statements about mechanism and preclinical activity describe research findings and do not establish safety or efficacy in humans.